Cancer-causing byproducts forced the drug maker to stop production, leaving many in the developing world without inexpensive options for treating HIV. Activists want Big Pharma to step in. Helen Palmer reports.
The diabetes drug could be linked to a greater chance of heart attack or stroke. And analysts worry GlaxoSmithKline might not have a blockbuster drug in the pipeline to boost sales. Stephen Beard reports.
The IRS is cracking down on hospitals that get tax breaks for providing charity care after a study finds many facilities spend just 1 percent of their revenue helping those who simply can't pay. Helen Palmer reports.
A Virginia judge today will hear from parents before sentencing three execs responsible for mis-marketing prescription painkiller OxyContin. The parents say their children are addicted to heroin because of it. Monica Brady-Myerov reports.
The steam-pipe explosion in Midtown Manhattan reminded New Yorkers just how vulnerable their aging infrastructure is. We asked Alisa Roth to look at the cost of keeping it up.
More people are combining tourism with cheaper dental care. Hungary is a big draw, and India's becoming a popular destination, too. But commentator Jean Roznik says some dentists offer the same service to a select few, right here at home.
The Federal Trade Commission heard today from food companies that market to children. And the mere mention of government regulation prompted those companies to crack down on themselves. Janet Babin reports.
Following troubling reports from a U.S. researcher about diabetes medication Avandia, German researchers have found that GSK's second-biggest seller doesn't appear to work, but does have plenty of negative side effects. Stephen Beard has details.
Health insurance woes abound in this country, but people with eating disorders often face an even steeper uphill battle with insurers, many of whom provide very limited coverage for what doctors call a very complex disease to treat. Rachel Dornhelm reports.
Democrats have made insurance coverage for psychiatric disease a high priority this summer. Separate bills are making their way through both houses of Congress, but business interests are supporting the Senate's version. Helen Palmer tells us why.
